The idea that young blood has almost magical properties, took place at the dawn of modern society. However, some experiments in this area still. Of course, the medieval ceremonies with the blood transfusion babies to the elderly no one is omitted. But not so long ago a California company Alkahest during the phase of preliminary tests were able to prove that in a special way prepared plasma of young blood helps to cope with the manifestations of Alzheimer’s disease.
Like blood will help to cure Alzheimer’s disease
The company Alkahest is developing treatments for neurodegenerative diseases for several years. Very heavy emphasis scientists companies make special proteins called “chronocide”. Chronocide contained in blood plasma and, according to some reports, a positive effect on the Central nervous system, restoring the work of brain neurons and promoting the regeneration of stem cells. It is known that the content granatino changes with age, decreasing significantly in old age. It is this gap, scientists company Alkahest and decided to fill.
This is interesting: For the treatment of Alzheimer’s disease would be to apply gene therapy.
In a recent study, scientists recruited a group of 40 patients suffering from Alzheimer’s disease. The scientists wanted to check to confirm whether their predictions as to whether to introduce a man a fraction of blood plasma is placed in her chronocinema GRF6019, it will slow down the disease. It is worth noting that this is the second phase of testing and for the first time on laboratory animals the result was positive. This time, all 40 participants of the experiment for five days were administered intravenously therapeutic plasma chronocinema GRF6019. After 12 weeks the procedure was repeated. Thus, before and after treatment patients were some of the most common tests to evaluate the depth of cognitive impairment in Alzheimer’s disease and senile dementia.
In the end it turned out that after 12 weeks of treatment parameters of patients on these tests remained at the same level. This may seem bad but actually it is not so. The fact is that in 12 weeks the test results was expected, as during this time the process of brain degeneration during the normal course of the disease to slow down simply could not.
Our results indicate the potential value of the protein fraction of the plasma GRF6019 in slowing the progression of Alzheimer’s, says the head of the Alkahest Carolee Nikolic. The development of effective treatments for this and other neurodegenerative diseases have been virtually unsuccessful for many decades. GRF6019 aimed at addressing the multiple mechanisms that underlie the development process. Such as, for example, the uncontrolled death of nerve cells.
To discuss this and other news, you can in our chat in Telegram.